Code for quantitative CT tissue characterization goes into effect on July 1.
The American Medical Association (AMA) has reportedly issued a new Category III Current Procedural Terminology (CPT) code that radiologists and other clinicians may employ for quantitative CT tissue characterization, according to Nanox and Nanox.AI.
The companies said this code (going into effect on July 1) may provide a pathway for broader use of their artificial intelligence (AI)-enabled HealthCCSng, a cardiac imaging modality which radiologists may use adjunctively with chest computed tomography (CT) to help quantify coronary artery calcium (CAC), a key biomarker of cardiovascular disease.
While assessing CAC with chest CT alone can be a time-consuming endeavor, Nanox noted the FDA-cleared HealthCCSng facilitates efficient analysis of non-gated CT scans, quantifies the amount of CAC and subsequently provides risk stratification for patients into three categories based on the CAC detected.
“AI-enabled technologies that are built into existing radiologist workflows can help them identify at-risk patients and provide enhanced clinical insights,” said Erez Meltzer, the chief executive officer for Nanox. “We believe this (CPT code) is an important milestone that will enable radiologists and physicians in the United States to provide their patients with better care and a promising step toward realizing … the growing importance of AI-based imaging technologies in value-based care.”
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
July 22nd 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.